• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用氯氮平治疗的精神分裂症患者的体重增加情况。

Weight gain among schizophrenic patients treated with clozapine.

作者信息

Lamberti J S, Bellnier T, Schwarzkopf S B

机构信息

Rochester Psychiatric Center, University of Rochester School of Medicine and Dentistry, NY.

出版信息

Am J Psychiatry. 1992 May;149(5):689-90. doi: 10.1176/ajp.149.5.689.

DOI:10.1176/ajp.149.5.689
PMID:1349460
Abstract

A retrospective chart review was used to assess weight changes in 36 chronic schizophrenic inpatients who were treated with clozapine after being treated with standard neuroleptics. The average weight gain during 6 months of clozapine treatment was 16.9 lb; 75.0% of the patients gained at least 10 lb. The results confirm previous findings of clozapine-associated weight gain.

摘要

通过回顾性病历审查来评估36名慢性精神分裂症住院患者的体重变化,这些患者在接受标准抗精神病药物治疗后使用氯氮平进行治疗。氯氮平治疗6个月期间的平均体重增加为16.9磅;75.0%的患者体重至少增加了10磅。这些结果证实了先前关于氯氮平相关体重增加的研究发现。

相似文献

1
Weight gain among schizophrenic patients treated with clozapine.使用氯氮平治疗的精神分裂症患者的体重增加情况。
Am J Psychiatry. 1992 May;149(5):689-90. doi: 10.1176/ajp.149.5.689.
2
Clozapine and weight gain.氯氮平与体重增加。
J Clin Psychiatry. 1994 Sep;55 Suppl B:157-60.
3
[Weight gain and clozapine].[体重增加与氯氮平]
Encephale. 1996 Oct;22 Spec No 3:77-9.
4
Clozapine-induced weight gain: prevalence and clinical relevance.氯氮平所致体重增加:患病率及临床相关性。
Am J Psychiatry. 1992 Jan;149(1):68-72. doi: 10.1176/ajp.149.1.68.
5
Differential effect of clozapine on weight: a controlled study.氯氮平对体重的差异影响:一项对照研究。
Am J Psychiatry. 1996 Jun;153(6):817-9. doi: 10.1176/ajp.153.6.817.
6
[Presentation of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine].[使用氯氮平治疗的精神分裂症患者出现强迫症状]
Psychiatr Prax. 1999 May;26(3):145-6.
7
Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.氯氮平治疗难治性精神分裂症:14例患者长达2年的开放性研究。
J Clin Psychiatry. 1989 Oct;50(10):389-91.
8
[Quality of life of schizophrenic patients and clozapine].[精神分裂症患者的生活质量与氯氮平]
Encephale. 1997 Sep;23 Spec No 4:12-6.
9
Effects of clozapine on smoking in chronic schizophrenic outpatients.氯氮平对慢性精神分裂症门诊患者吸烟的影响。
J Clin Psychiatry. 1995 Aug;56(8):344-6.
10
Association of initial antipsychotic response to clozapine and long-term weight gain.氯氮平初始抗精神病反应与长期体重增加的关联。
Am J Psychiatry. 2006 Jul;163(7):1276-9. doi: 10.1176/ajp.2006.163.7.1276.

引用本文的文献

1
Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.氯氮平相关代谢紊乱与精神分裂症患者 CYP3A4 表达的相关性。
Sci Rep. 2020 Dec 4;10(1):21283. doi: 10.1038/s41598-020-78474-0.
2
Antipsychotic-Induced Weight Gain and Clinical Improvement: A Psychiatric Paradox.抗精神病药物所致体重增加与临床改善:一种精神科悖论。
Front Psychiatry. 2020 Nov 3;11:560006. doi: 10.3389/fpsyt.2020.560006. eCollection 2020.
3
Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action.
氯氮平治疗帕金森病静止性震颤:疗效、不良反应及可能作用机制的综述
Mov Disord Clin Pract. 2015 Dec 30;3(2):116-124. doi: 10.1002/mdc3.12266. eCollection 2016 Mar-Apr.
4
The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.抗精神病药物所致体重增加与治疗益处之间的复杂关系:一项系统综述及对治疗的启示
Front Neurosci. 2018 Jan 22;11:741. doi: 10.3389/fnins.2017.00741. eCollection 2017.
5
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.难治性精神分裂症:抗精神病药物基因组学的当前见解
Pharmgenomics Pers Med. 2016 Nov 7;9:117-129. doi: 10.2147/PGPM.S115741. eCollection 2016.
6
Dietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain.膳食果糖和GLUT5转运蛋白活性导致抗精神病药物引起的体重增加。
Schizophr Bull. 2016 Sep;42(5):1270-9. doi: 10.1093/schbul/sbw037. Epub 2016 Apr 7.
7
Obesity and psychotropics.肥胖与精神药物。
CNS Neurosci Ther. 2012 Jan;18(1):57-63. doi: 10.1111/j.1755-5949.2011.00232.x. Epub 2011 May 9.
8
Weight gain, obesity, and psychotropic prescribing.体重增加、肥胖与精神药物处方
J Obes. 2011;2011:893629. doi: 10.1155/2011/893629. Epub 2011 Jan 17.
9
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.对于使用氯氮平而非奥氮平治疗的非糖尿病精神分裂症患者,腰围是胰岛素抵抗的最佳人体测量学预测指标。
J Psychiatr Pract. 2009 Jul;15(4):251-61. doi: 10.1097/01.pra.0000358312.99233.ef.
10
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.一项关于罗格列酮治疗精神分裂症患者氯氮平所致糖代谢损害的双盲、安慰剂对照试验。
Acta Psychiatr Scand. 2009 Jun;119(6):457-65. doi: 10.1111/j.1600-0447.2008.01325.x. Epub 2009 Jan 12.